PCLAF and allergic disease: Thus, the observations that similar immune cells and soluble factors are implicated in the pathogenesis of pulmonary fibrosis and allergy conditions provide a rationale for using the antiallergic drug rupatadine to target H1 or PAF signaling for treatment of pulmonary fibrosis.